Detalles de la búsqueda
1.
Advancing assessment of asthma control with a composite tool: The Asthma Impairment and Risk Questionnaire.
Ann Allergy Asthma Immunol
; 2024 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494113
2.
Assessing meaningful change in the Asthma Impairment and Risk Questionnaire.
Ann Allergy Asthma Immunol
; 2024 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38369256
3.
The Asthma Impairment and Risk Questionnaire enhances the assessment of asthma control.
Ann Allergy Asthma Immunol
; 131(4): 436-443.e1, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37105501
4.
Evaluating construct validity of the Asthma Impairment and Risk Questionnaire using a 3-month exacerbation recall.
Ann Allergy Asthma Immunol
; 128(5): 544-552.e3, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123077
5.
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
CNS Spectr
; 19(6): 528-34, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24642260
6.
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
Hum Psychopharmacol
; 29(6): 528-36, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25274271
7.
Sodium Zirconium Cyclosilicate in Chronic Kidney Disease, Hyperkalemia, and Metabolic Acidosis: NEUTRALIZE Randomized Study.
Kidney360
; 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38622759
8.
Validation of the Onset of Effect Questionnaire in Participants With Chronic Obstructive Pulmonary Disease.
Chronic Obstr Pulm Dis
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38722709
9.
Impact of Clinical Characteristics and Biomarkers on Asthma Impairment and Risk Questionnaire Exacerbation Prediction Ability.
J Allergy Clin Immunol Pract
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705273
10.
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.
JACC Heart Fail
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38878009
11.
Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease.
Clin Kidney J
; 16(7): 1160-1169, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37398685
12.
Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence.
J Asthma Allergy
; 16: 59-72, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36636702
13.
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
Int J Psychiatry Clin Pract
; 16(2): 121-31, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22296512
14.
The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations.
J Allergy Clin Immunol Pract
; 10(12): 3204-3212.e2, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998877
15.
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Int J Geriatr Psychiatry
; 26(6): 564-72, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20827794
16.
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment.
Respir Med
; 176: 106278, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33387985
17.
Use of a Digital Chronic Obstructive Pulmonary Disease Respiratory Tracker in a Primary Care Setting: A Feasibility Study.
Pulm Ther
; 7(2): 533-547, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463947
18.
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
J Clin Psychopharmacol
; 30(3): 300-5, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20473067
19.
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure.
J Allergy Clin Immunol Pract
; 8(7): 2263-2274.e5, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32387166
20.
Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.
Circ Cardiovasc Qual Outcomes
; 13(5): e006182, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32393129